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A B S T R A C T
Overactive bladder (OAB) is a common, often debilitating, condition defined as urgency and urge incontinence, usu-
ally with frequency and nocturia. The use of muscarinic receptor antagonists are the mainstay of treatment, but their
non-selectivity can result in unacceptable adverse effects that limit their usefulness. The purpose of this study was to eval-
uate 2 of the newer antimuscarinic agents, solifenacin and darifenacin, which demonstrate greater selectivity, in order to
compare their tolerance and effectiveness. This was a multicentre, prospective, randomised, comparative (1:1) open-label
study conducted in 4 centres comprising Slovenian gynaecologists and urologists. A total of 77 female patients with OAB
were enrolled who received either solifenacin 5 mg or darifenacin 7.5 mg once daily. Study measurements consisted of
changes in OAB symptoms and quality of life (QOL) evaluations after 1 and 3 months of treatment. Both treatment
groups showing a reduction in all OAB symptoms but with no notable difference being seen between the 2 groups. Soli-
fenacin though showed statistically greater improvements in QOL, better overall treatment satisfaction, and a decreased
incidence of dry mouth after 3 months of treatment compared to the darifenacin group. This study demonstrates interest-
ing initial results and indicates that these 2 drugs have a different profile that may confer an advantage to patients, but
further methodologically rigorous studies comparing the use of solifenacin and darifenacin in OAB are required to es-
tablish the differences between these drugs over longer periods of treatment.
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Introduction
Overactive bladder syndrome (OAB) comprises a set
of symptoms, among which the most significant are ur-
gency (a sudden, compelling desire to pass urine which is
difficult to defer), increased daytime frequency (frequent
voiding by day), urge incontinence (involuntary leakage
accompanied by, or immediately preceded by, urgency),
and nocturia (a need to wake once or more at night in or-
der to void)1.
OAB is a common, serious and often debilitating con-
dition, and is associated with high economic and social
costs2. Epidemiological surveys estimate that the condi-
tion affects approximately 50 million adults in Europe
and the USA, with prevalence increasing with age3–5. The
prevalence of OAB is approximately 16% in men and
women aged ³40 years, and it is associated with a signifi-
cant impairment in quality of life (QOL)3,4,6–8. Appro-
ximately one third of OAB sufferers (32%) are depressed,
and approximately one quarter (28%) feels extremely
stressed because of this condition. Urge urinary inconti-
nence is especially troublesome since it causes the af-
fected person great concern and embarrassment, conse-
quently limiting their everyday activities, both at home
and at work8.
OAB is a chronic condition requiring long-term, con-
tinuous treatment, usually comprising of an integrated
approach involving behavioural therapy (scheduled void-
ing), physical therapies (pelvic floor muscle training,
nonimplantable electrical stimulation) and pharmacolog-
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ical therapy. Anticholinergic drugs, commonly toltero-
dine and oxybutynin, represent the 'gold standard' of
pharmacological treatment. These drugs competitively
inhibit postsynaptic muscarinic receptors, thereby pre-
venting detrusor muscle contraction. However, the use of
these antimuscarinic agents has been limited by sub-op-
timal efficacy or adverse events (AEs) due to generalised
muscarinic receptor blockade9.
Anticholinergic agents exert their effect non-selec-
tively on the 5 sub-types of muscarinic (M) receptors and
hinder their activity, thereby giving rise to a range of
AEs. M3 receptors are found in the salivary glands, soft
muscles of the intestine and in the ciliary apparatus of
the eye, therefore blockade of these receptors results in
dry mouth, the most frequent and generally most prob-
lematic AE which often leads to treatment disconti-
nuation10–12. In addition, constipation and blurred vision
are frequently reported. Other AEs occur less frequently,
however, blockade of M1 receptors in the central nervous
system (CNS) can result in serious cognitive distur-
bances, such as impaired concentration and memory
loss.
In recent years, 2 new drugs have become available
for the treatment of OAB: solifenacin and darifenacin.
Solifenacin was launched throughout most of Europe in
2004 and is available in both 5mg and 10mg formula-
tions, offering flexible once-daily dosing for alleviating
symptoms of OAB, specifically urge incontinence and in-
creased urinary frequency through its action on musca-
rinic receptors. Darifenacin 7.5mg and 15mg was also
granted Marketing Authorisation by the European Com-
mission for the treatment of OAB in 2004. Initial studies
have shown that the greater selectivity of these drugs re-
sults in a smaller incidence of AEs and improved clinical
efficacy13–16. However, head-to-head studies comparing
solifenacin and darifenacin are lacking and, therefore,
this study aimed to compare the efficacy and tolerability
of these 2 antimuscarinic agents.
The objective of this patient-oriented study was to as-
sess the clinical efficacy of solifenacin and darifenacin
(SOLIDAR Study: SOLIfenacin DARifenacin) in women
with OAB after 1 and 3 months of treatment. The pri-
mary endpoint of this study was urgency, specifically the
frequency and intensity of urge episodes.
Materials and Methods
This study comprised a multicentre, prospective, ran-
domised, comparative (head-to-head) open-label study, in
which 100 female patients with OAB were planned to be
enrolled by 8 Slovenian gynaecologists and urologists in
5 centres. Patients were enrolled between October 2007
and October 2008 on a consecutive basis, with 100 pa-
tients randomised on a 1:1 basis to one of 2 drugs,
solifenacin 5 mg or darifenacin 7.5 mg from a computer
generated randomisation list. The study was approved by
the Ethics Committee at the Ministry of Health, Repub-
lic of Slovenia and IRB University Medical Center, Ma-
ribor. All patients provided written informed consent
prior to participation in any study-specific procedures.
Patient inclusion criteria comprised females with idi-
opatic OAB, defined as urgency intensity and urgency
urinary incontinence (UUI) of ³3 on the Urgency Percep-
tion Scale (UPS) and frequency of ³1 urgency episodes
(UE) per day. Patients were required not to have received
any anticholinergic drugs for at least 6 months prior to
study inclusion. Patients were excluded from participa-
tion if they were pregnant, suffered from angular glau-
coma, urinary infection, urinary tract stones, bladder
disease (i.e. stones or tumours), or if they were incapable
of actively participating in the study (e.g. dementia). Pa-
tients with neurogenic OAB and those with severe ortho-
paedic difficulties (e.g. need for crutches or wheelchair
etc.) were also excluded from the study.
Treatment was evaluated at baseline, and at 1and 3
months post-treatment in order to assess subjective im-
provement. Patients were issued with 2 questionnaires:
the Urogenital Distress Inventory (UDI) and the Inconti-
nence Impact Questionnaire (IIQ), these being patient-
-reported outcomes instruments used to determine the
effect of treatment from the patient’s perspective. Pa-
tients were also issues with a Visual Analogue Scale
(VAS) and Urgency Perception Scale (UPS). Secondary
endpoints comprised the occurrence of a pre-defined list
of AEs and treatment success.
The study schedule consisted of 4 clinic visits. At the
first visit (baseline) patient history was taken (including
date of birth, body weight, height, body mass index
(BMI), gynaecological history, duration of OAB symp-
toms, duration of urinary incontinence, previous treat-
ment of incontinence, and concomitant diseases and the-
rapies). A clinical examination was also performed and a
urine sample was taken for analysis. At the end of the
first visit, patients were issued with 2 questionnaires:
the Urogenital Distress Inventory (UDI) and the Inconti-
nence Impact Questionnaire (IIQ). The UDI question-
naire is used for screening for stress, irritative and ob-
structive symptoms while the IIQ questionnaire asks
how these symptoms affect the quality of life (QoL) of af-
fected women in terms of physical activity (PA), travel
(T), social relations (SR), and emotional health (EH)17.
Visit 2 was performed 7 days following the baseline
visit. Information about voiding and the UDI and IIQ
questionnaire data were checked for accuracy and urinal-
ysis results were checked for normality. Patients were
then administered their first dose of study medication
comprising either solifenacin 5 mg or darifenacin 7.5 mg,
with both drugs taken at a dose of one tablet during the
evening. The physician requested that the patient did
not change their habits during the course of the study,
for example by performing bladder training or pelvic
floor muscle training, and patients were asked to drink
the same quantity of liquid during the study as prior to
study participation. Patients then received 2 forms for
completion 3 days before the next clinic visit; one to re-
cord details of any AEs and the other a voiding diary to
be used over a 3-day period.
Visit 3 was performed 1 month after commencing
treatment. During the visit, voiding diaries were checked
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for completion, AEs assessed, and an assessment made of
the intensity of OAB symptoms and treatment efficacy
from the patient’s perspective. Patients then received a
new voiding diary for completion, together with UDI and
IIQ questionnaires.
The final visit, Visit 4, was scheduled 3 months after
starting the treatment. Voiding diaries and UDI and IIQ
questionnaires were checked for completion, and any
AEs that had emerged since the previous follow-up visit
were noted. OAB symptoms and treatment efficacy were
assessed, and each patient was asked to provide an esti-
mate of treatment success using a Visual Analogue Scale
(VAS). Results of a second urinalysis were assessed.
Finally, a decision was taken as to whether the patient
would continue with treatment at the same or at a higher
dose.
Statistical Analysis
Scores were calculated for the following study end-
points: urgency (how strong), urgency (how often), ur-
gency (how bothersome), frequency, nocturia, number of
pads used, IIQ total score, UDI total score, and subjective
success. All scores were recorded on a scale of 0 to 10,
with the exception of urgency (how bothersome) that was
recorded on a scale of 0–100.
Although there were departures from the normal dis-
tribution, median and mean scores, lower/upper quar-
tiles, and standard deviations were used as a consistent
and convenient method to summaries the results. Data
were summarized by treatment, and changes from base-
line to 1 and 3 months presented. Due to non-normal dis-
tributions, treatment differences were tested using the
Wilcoxon Rank Sum Test. Treatment differences in the
numbers continuing at the same dose were tested using
Fisher’s Exact Test. Spearman correlation coefficients
(with 95% confidence intervals) were calculated for im-
provement scores versus improvement in symptoms. Fol-
lowing good statistical practice no significance testing of
baseline data were performed.
As this was regarded as an exploratory study, no for-
mal adjustments for multiple significance testing were
performed. Statistical analysis was performed using SAS
statistical software (SAS Institute Inc., Cary, NC, USA).
Results
Four centres participated in this study, recruiting a
total of 77 patients (40 solifenacin, 37 darifenacin). Six-
teen patients withdrew prematurely from the study (8
solifenacin, 8 darifenacin) and 61 patients completed the
study (solifenacin 32 (80%), 29 darifenacin (78.4%)). The
reasons for withdrawal were adverse events in (8 pa-
tients), lack of efficacy (4 patients), withdrawal of con-
sent (3 patients), and one patient was advised to stop tak-
ing study medication on psychiatric advice (Figure 1).
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One darifenacin patient was withdrawn before receiving
any treatment so was not included in any of the analyses.
The median age of patients enrolled into the study
was 54 years (X: 54.8 years (SD: 11.5)) (median 52 years
in the solifenacin group and 56 years in the darifenacin
group), and the median BMI was 26.9 kg/m2 (X: 27.6
kg/m2 (SD: 5.0) (median 26.4 kg/m2 in the solifenacin
group and 28.4 kg/m2 in the darifenacin group). The me-
dian duration of prior urgency incontinence was 60
months (X: 86.0 months (SD: 82.6)) (54 months in the
solifenacin group and 72 months in the darifenacin group)
and the median duration of urge urinary incontinence
was 36 months (X: 46.5 months (SD: 55.7)) (27 months in
the solifenacin group and 36 months in the darifenacin
group).
Analysis of OAB symptoms at baseline were generally
similar between the 2 treatment groups, although ur-
gency (bothersome) scores were higher in the darifenacin
group, and frequency scores were higher in the solife-
nacin group (Table 1). Following 1 month and 3 months
of treatment, all measured OAB symptoms decreased,
with no statistically significant treatment differences be-
ing seen between the groups (Table 1). However, it is of
note that nocturia decreased to a greater extent in the
solifenacin group at 1 month and this group also used
less incontinence pads than those in the darifenacin
group at 3 months (Table 1).
The majority of patients in the solifenacin group who
completed the study maintained the same dose post-
-study (21 patients, 66%), with only 4 patients (13%) con-
sidered to need an increase in dose to maintain efficacy.
However, in the darifenacin group only 11 patients (38%)
who completed then maintained the same dose, with 13
patients (45%) considered to need an increase in dose to
maintain efficacy (treatment difference: p= 0.041).
Evaluation of the effects on QOL were assessed using
the IIQ and UDI questionnaires (Table 2). In both the
UDI and IIQ questionnaires, patients treated with soli-
fenacin indicated a greater improvement in QOL com-
pared to patients treated with darifenacin, and for the
IIQ total score the difference between the 2 groups
reached statistical significance (p=0.018). The social re-
lationship component of the IIQ also showed a signifi-
cant difference between the groups in favour of solife-
nacin (p=0.02), with the emotional health and transport
components also bordering on statistical significance (p=
0.06 and p=0.05, respectively).
Overall patient subjective and objective assessment of
treatment improvement was higher for solifenacin com-
pared to darifenacin, with the difference again being sta-
tistically significant in favour of solifenacin (p=0.01 for
subjective improvement) (Table 3).
AEs of dry mouth, constipation, blurred vision, head-
ache, dizziness, concentration problems, memory prob-
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TABLE 1
TREATMENT DIFFERENCE IN OAB SYMPTOMS OVER 1 AND 3 MONTHS OF TREATMENT
Baseline Change from Baseline
Solifenacin
Median
X (SD)
N=40
Darifenacin
Median
X (SD)
N=36
Solifenacin
Median X (SD) N=40
Darifenacin
Median X (SD) N=36
Treatment difference:
Median X (SD)
1 month
N=39
3 months
N=32
1 month
N=33
3 months
N=29
1 month
N=33
3 months
N=29
Urgency
(how strong)
3.0
3.2 (0.6)
3.0
3.1 (0.5)
–1.0
–0.8 (0.7)
–1.0
–1.1 (0.8)
–1.0
–0.6 (0.7)
–1.0
–0.8 (0.8)
0.0
–0.1 (0.7)
(p=0.55)
0.0
–0.3 (0.8)
(p=0.23)
Urgency
(how often)
6.0
5.7 (0.99)
7.0
5.9 (1.5)
–1.0
–1.0 (1.1)
–1.0
–1.0 (1.95)
–1.0
–1.0 (1.2)
–2.0
–1.6 (1.8)
0.0
0.03 (1.2)
(p=0.90)
0.0
–0.4 (1.9)
(p=0.66)
Urgency (how
bothersome)
70.5
72.8 (17.3)
75.5
73.2 (20.2)
–20.0
–20.1 (19.95)
–28.5
–30.8 (27.7)
–10.0
–14.2 (22.8)
–26.0
–24.6 (24.6)
–8.0
–5.9 (21.3)
(p=0.19)
–9.0
–6.2 (26.3)
(p=0.34)
Frequency
9.3
9.3 (3.2)
7.9
8.9 (4.1)
–1.4
–1.78 (2.0)
–1.7
–2.17 (2.5)
–1.4
–2.0 (2.7)
–1.4
–2.1 (3.4)
0.0
0.3 (2.4)
(p=0.82)
–0.3
–0.1 (2.99)
(p=0.70)
Nocturia
2.5
2.5 (1.6)
2.3
2.6 (1.3)
–1.0
–1.1 (1.1)
–1.0
–1.2 (1.1)
–0.4
–0.5 (1.1)
–1.0
–0.8 (1.3)
–0.6
–0.5 (1.1)
(p=0.051)
–0.3
–0.3 (1.2)
(p=0.43)
Number
of pads
2.9
2.8 (2.4)
2.4
2.9 (2.9)
–0.3
–0.6 (1.8)
–0.7
–1.1 (1.5)
–0.3
–0.4 (2.6)
–0.3
–0.4 (2.3)
0.0
–0.3 (2.2)
(p=0.76)
–0.6
–0.7 (1.9)
(p=0.19)
X = Mean; SD = standard deviation; p-values calculated using Wilcoxon Rank Sum Test
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lems, and insomnia were solicited at the 1 month and 3
month assessments, as well as at baseline. Symptoms of
dry mouth and constipation increased during the first
month of treatment in both groups, but by 3 months of
treatment had decreased again to baseline levels, with
the exception of dry mouth in the darifenacin group,
where 62% of patients still reported symptoms after 3
months of treatment (compared to only 41% in the solife-
nacin group) (Table 4).
Discussion
OAB is a common, often debilitating, condition de-
fined by the International Continence Society as urgency,
with or without urge incontinence, usually with fre-
quency and nocturia18, and is associated with high eco-
nomic and social costs2. Patients commonly state that the
symptoms of urinary urgency has a significant effect on
their QOL19. The use of muscarinic receptor antagonists
are the mainstay of treatment, but their non-selectivity
can result in unacceptable AEs that limit their useful-
ness. Two newer antimuscarinic agents, solifenacin and
darifenacin, which demonstrate greater selectivity, were
evaluated in this small, prospective study in order to
compare their effectiveness.
Solifenacin and darifenacin have been shown by pre-
vious research to exhibit lower AEs rates but with simi-
lar efficacy rates to established drugs in this field such as
tolterodine and oxybutinin15. Our hypothesis for the de-
sign of this study was that selective inhibition of M3 re-
ceptors by both drugs would effectively improve OAB
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TABLE 2
INCONTINENCE IMPACT QUESTIONNAIRE (IIQ) AND UROGENITAL DISTRESS INVENTORY (UDI) RESULTS
Median baseline value (lower – upper quartile)
Mean baseline value (SD)
Treatment difference from
baseline to 3 months
Median X (SD) N=29Solifenacin N=40 Darifenacin N=36
IIQ Score
Total score
232.9 (100.9–302.7)
211.8 (113.5)
256.7 (161.0–309.8)
231.6 (109.7)
–34.9
–35.9 (79.1)
(p=0.018)
Emotional health
39.6 (10.8–74.9)
43.9 (33.7)
50.0 (22.2–77.7)
49.3 (31.5)
–8.3
–11.0 (21.6)
(p=0.057)
Physical activity
63.9 (41.7–83.3)
60.0 (27.3)
72.2 (44.4–88.8)
64.1 (28.6)
–5.6
–6.9 (19.7)
(p=0.14)
Social relationship
37.8 (23.3–70.0)
44.9 (30.7)
60.0 (26.6–76.6)
52.1 (31.3)
–10.0
–8.7 (18.0)
(p=0.020)
Transport
70.0 (30.6–94.4)
63.0 (32.2)
72.2 (44.4–91.6)
67.6 (29.0)
–5.7
–9.31 (21.3)
(p=0.051)
UDI Score
Irritative symptoms
50.0 (36.1–72.2)
54.0 (24.5)
66.7 (50.0–83.3)
66.5 (20.5)
–5.6
–5.7 (25.4)
(p=0.34)
Stress symptoms
50.0 (33.3–66.7)
49.6 (32.6)
58.4 (33.3–100.0)
59.3 (36.0)
0.0
–7.5 (30.9)
(p=0.46)
Obstructive symptoms
15.1 (7.6–27.2)
20.4 (18.6)
27.2 (12.1–42.4)
26.4 (17.8)
–1.4
–1.1 (14.7)
(p=0.58)
p-values calculated using Wilcoxon Rank Sum Test
TABLE 3
SUBJECTIVE SUCCESS (VAS SCORE)
3 months
N Median (25–75 perc.)
Solifenacin 32 84 55.0–92.5
Darifenacin 29 55 33.0–88.0
Treatment difference in
change from baseline
Median 22.5, p=0.010
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symptoms, as evidenced by decreased incontinence pad
use and improved QOL. This assumption was met, with
both treatment groups showing a reduction in all OAB
symptoms. However, solifenacin showed statistically
greater improvements in quality of life (IIQ score), better
overall treatment satisfaction, and a decreased incidence
of dry mouth after 3 months of treatment compared to
patients treated with darifenacin.
These results concur with the findings of Kobayashi
et al who found that solifenacin provided a promising
therapeutic advantage for reducing AEs such as dry
mouth, due to its greater selectivity for bladder smooth
muscle cells over salivary gland cells20. This seems to cor-
relate with the results of our study, where increased pa-
tient satisfaction was seen with solifenacin treatment,
with this translating into an improvement in QoL In the
long term it can be hypothesised that these advantages
may increase patient compliance and thus maintain the
effects of treatment over a longer period of time.
It is important to note that this was the first head-to-
-head study comparing these antimuscarinic drugs. How-
ever, it was only a small study so a calculation to establish
sample size and power was not performed and subse-
quently the study could have been underpowered. Also
the full number of intended patients were not enrolled
due to difficulties enrolling patients and the fact that
very few centres deal with treatment of this condition in
Slovenia. Finally, neither physicians nor patients were
blinded to the treatments administered which could have
introduced significant bias. Despite these limitations,
this study provides an interesting indicator that these 2
drugs have a different profile that may confer an advan-
tage to patients with this distressing condition, but a fur-
ther large-scale, long-term study would be needed to con-
firm our findings.
In conclusion, solifenacin and darifenacin are both ef-
fective and well-tolerated drugs for the treatment of
OAB. The results of this study indicate that these 2
drugs have a different profile that may confer an advan-
tage to patients with OAB. Whilst this study demon-
strates interesting initial results, further methodologi-
cally rigorous studies comprising large, long-term, pros-
pective, randomised clinical trials comparing the use of
solifenacin and darifenacin in OAB are required to estab-
lish the effectiveness of these drugs over longer periods
of treatment.
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TABLE 4
SOLICITED ADVERSE EVENTS
Solicited Adverse
events
Solifenacin N=40
N (%)
Darifenacin N=36
N (%)
Baseline
N=40
1 month
N=39
3 months
N=32
Baseline
N=36
1 month
N=35
3 months
N=29
Dry mouth 15 (38%) 24 (62%) 13 (41%) 17 (47%) 27 (77%) 18 (62%)
Constipation 16 (40%) 17 (45%) 8 (25%) 10 (28%) 15 (44%) 8 (28%)
Blurred vision 16 (40%) 13 (33%) 10 (31%) 16 (44%) 11 (33%) 9 (31%)
Headache 12 (30%) 11 (28%) 5 (16%) 16 (44%) 13 (38%) 3 (21%)
Dizziness 12 (30%) 10 (26%) 7 (22%) 15 (42%) 8 (24%) 4 (14%)
Lack of concentration 15 (38%) 9 (23%) 8 (25%) 14 (39%) 11 (33%) 8 (28%)
Memory problems 19 (48%) 11 (28%) 10 (31%) 20 (56%) 11 (33%) 9 (31%)
Insomnia 17 (43%) 8 (21%) 9 (28%) 18 (50%) 12 (36%) 7 (24%)
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USPOREDBA DVA SELEKTIVNA ANTIMUSKARINSKA LIJEKA (SOLIFENACIN I DARIFENACIN)
U @ENA S PREKOMJERNO AKTIVNIM MOKRA]NIM MJEHUROM
S A @ E T A K
Prekomjerno aktivan mokra}ni mjehur (OAB) je ~esto stanje definirano urgencijom i urgentnom inkontinencijom,
te u~estalim dnevnim i no}nim mokrenjem. Terapija izbora danas je primjena antimuskarinskih lijekova. Medjutim,
ograni~avaju}i ~imbenik primjene navedenih lijekova je njihova neselektivnost {to mo`e rezultirati ne`eljenim u~in-
cima i nuspojavama. Cilj ove studije je usporediti u~inkovitost i podno{ljivost solifenacina i darifenacina, dva novija
visokoselektivna antimuskarinska lijeka. U multicentri~nu, prospektivnu, randomiziranu »open-label« studiju uklju-
~eno je 77 pacijentica s OAB-om koje su uzimale 5 mg solifenacina ili 7.5 mg darifenacina u jednokratnoj dnevnoj dozi.
Procjena u~inkovitosti oba lijeka temeljila se na subjektivnoj i objektivnoj procjeni smanjenja OAB simptoma i kvalitete
`ivota nakon mjesec i tri mjeseca lije~enja. U obje ispitivane skupine dokazana je podjednaka u~inkovitost u smanjenju
svih simptoma OAB-a. U skupini pacijentica koje su koristile solifenacin dokazano je statisti~ki zna~ajno pobolj{anje
kvalitete `ivota, bolje ukupno zadovoljstvo i smanjena u~estalost suho}e ustiju nakon tri mjeseca lije~enja u usporedbi
sa skupinom pacijentica koje su koristile darifenacin. Ova studija je dokazala da solifenacin i darifenacin predstavljaju
u~inkovite i dobro podno{ljive lijekove u lije~enju OAB-a. Rezultati ove studije da primjena oba lijeka s razli~itim pro-
filom glede potencijalnih nuspojava mo`e zna~ajno pobolj{ati u~inkovitost i sigurnost lije~enja u pacijentica s OAB. Za
nadati se da }e budu}e ve}e, prospektivne i randomizirane klini~ke studije jasnije pozicionirati u~inkovitost i podno{lji-
vost solifenacina i darifenacina u `ena s prekomjerno aktivnim mokra}nim mjehurom.
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